Antibody Therapeutics Market

The global antibody therapeutics market is projected to reach USD 597.1 billion by 2035, up from USD 311.2 billion in 2026, at a CAGR of 7.5% over the forecast period. The antibody therapeutics market is experiencing rapid growth, driven by the rising prevalence of cancer, autoimmune disorders, and other chronic diseases, as well as the increasing demand for targeted and personalized treatments. Advances in antibody engineering, including bispecific and multi-specific antibodies, antibody-drug conjugates, Fc engineering, and humanized antibodies, are improving therapeutic specificity, efficacy, and safety. Expanding clinical indications, strong biopharmaceutical R&D investment, and a growing pipeline of next-generation biologics are further accelerating market development.

The global market for antibody therapeutics is competitive, with companies such as AbbVie, Inc., Merck, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, MacroGenics, Inc., Sanofi, Amgen, GSK Plc., Eli Lilly and Company, Pfizer, Inc., and Daiichi Sankyo, Inc., among others. These market players have pursued strategies such as product launches, acquisitions, agreements, collaborations, and expansions to strengthen their market positions.

To know about the assumptions considered for the study download the pdf brochure

Merck & Co., Inc. (US): Merck, known as MSD outside the US and Canada, is a major participant in the antibody therapeutics market, with a strong emphasis on oncology and immunotherapy. Its antibody portfolio is anchored by KEYTRUDA (pembrolizumab), an anti-PD-1 monoclonal antibody developed across numerous cancer types and treatment combinations. The company is also advancing monoclonal antibodies, antibody-drug conjugates, and other targeted biologics through its clinical pipeline. Merck’s growth strategy includes expanding approved indications, evaluating antibody combinations with chemotherapy and targeted agents, and strengthening its pipeline through acquisitions, licensing agreements, and research collaborations.

Johnson & Johnson (US): Johnson & Johnson is a major participant in the antibody therapeutics market, supported by its strong Innovative Medicine business and biologics presence across oncology, immunology, and inflammatory diseases. Its antibody-related commercial products include DARZALEX/DARZALEX FASPRO for multiple myeloma, RYBREVANT/RYBREVANT FASPRO for EGFR-driven lung cancer, TECVAYLI as a BCMAxCD3 bispecific antibody, TALVEY as a GPRC5DxCD3 bispecific antibody, and immunology biologics such as TREMFYA, STELARA, and SIMPONI/SIMPONI ARIA. The company’s pipeline focus is concentrated on oncology and immunology, including lifecycle expansion of approved antibodies, new combination regimens, bispecific antibodies, subcutaneous formulations, and targeted biologics for solid tumors, hematologic malignancies, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Regeneron Pharmaceuticals Inc. (US): Regeneron is a key antibody-focused biopharmaceutical company with strengths in discovery, development, and commercialization of monoclonal antibodies and next-generation biologics. The company is well placed in the antibody therapeutics market due to its established biologics platform, late-stage clinical assets, and focus on high-value areas such as oncology, immunology, ophthalmology, and rare diseases.

Market Ranking

Market competition is analyzed across the antibody therapeutics market landscape. 

The market for antibody therapeutics is competitive, with the top five key players collectively holding approximately 35-40% of the total market share. Merck & Co., Inc. (US) has a significant market share, reflecting its extensive influence through a high-revenue product portfolio. Johnson & Johnson (US) also holds a substantial market share, with the Darzalex and Stelara brands generating significant revenue. Regeneron Pharmaceuticals, Inc., Sanofi, and AbbVie have also captured significant portions of the market by focusing on commercialized product growth as well as research and development to introduce innovative products that strengthen their market presence. Regional & emerging players hold the remaining 60-65% of the market, leading to significant consolidation. Several key factors contribute to the growth of this market, including product innovation, strategic partnerships, and the increasing demand for antibody therapeutics.

Related Reports:

Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), RoA (IV, SC), Region, Competition - Global Forecast to 2035

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]